-
Long ago, one of my mentors staunchly opined that "only a 'real doctor' should be allowed to testify that a 'real doctor' breached the standard of care." Two recent high-level court decisions upholding tort state reforms bring us closer to that reality, i.e., requiring the plaintiff's physician expert to actually practice medicine in order to testify in a medical malpractice lawsuit.
-
This is the first of a two-part series on missed myocardial infarction [MI] cases. This month, we report on the best practices for reducing liability risks involving triage, and review cases of chest pain patients involving adverse outcomes in ED waiting rooms.
-
"Unfortunately, while health care access continues to decline, the episodes of bad outcomes in waiting rooms can only rise.
-
-
-
-
The experience of two referral centers in London, UK, on the short-term outcomes of high-intensity-focused ultrasound (HIFU) for prostate cancer ablation, revealed the approach to be effective in short-term control but not without toxicity.
-
Allogeneic hematopoietic cell transplantation (alloHCT) is recommended for consolidation among poor-risk AML patients in CR1, but controversy remains for intermediate-risk disease.
-
In a retrospective cohort study among 2,201 five-year survivors of Hodgkin lymphoma, there was a two- to three-fold increased risk of stroke and TIA.
-
For patients with ER-, PR-, HER 2- breast cancer, neoadjuvant treatment, with eight weekly cycles of cisplatin, epirubicin, and paclitaxel (and G-CSF), resulted in impressive response rates and promising long-term, disease-free survival.
